<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>MicroRNAs have been implicated in the regulation of several cellular signaling pathways of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cells </plain></SENT>
<SENT sid="1" pm="."><plain>Although emerging evidence proves that microRNA (miR)-106a is expressed highly in <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and stool samples of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients; whether or not miR-106a mediates <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>We show here that miR-106a is highly expressed in metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells, and regulates <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell migration and invasion positively in vitro and in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>These phenotypes do not involve confounding influences on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell proliferation </plain></SENT>
<SENT sid="4" pm="."><plain>MiR-106a inhibits the expression of transforming growth factor-Î² receptor 2 (TGFBR2), leading to increased <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell migration and invasion </plain></SENT>
<SENT sid="5" pm="."><plain>Importantly, miR-106a expression levels in primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> are correlated with clinical <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">cancer progression</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>These observations indicate that miR-106a inhibits the anti-metastatic target directly and results in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell migration and invasion </plain></SENT>
</text></document>